Tyrosine Kinase Inhibitors Market to Partake Significant Development by 2025

Tyrosine kinase is a subclass of protein kinases family of enzymes responsible for phosphorylation. These are directly involved in cell division. Hence, kinase inhibitors are used in cancer treatment to prevent unregulated cellular proliferation. Tyrosine kinase inhibitors (TKI) comes under targeted therapy. TKI can be taken orally as pills. Only specific cancer cells can be treated in targeted therapy while causing minimum damage to normal cells. In chronic myeloid leukemia (CML), tyrosine kinase inhibitors target the abnormal BCR-ABL (Abelson murine leukemia) protein that causes unregulated CML cell growth and stops its function which causes the death of CML cells.

The global Tyrosine Kinase Inhibitors Market can be segmented based on product type, treatment type, and end-user. In terms of product type, tyrosine kinase inhibitors market can be bifurcated into receptor tyrosine kinase inhibitors and non-receptor tyrosine kinase inhibitors. The receptor tyrosine kinase inhibitors family include epidermal growth factor receptor family (EFGR), insulin-like growth factor receptor (IGF-R), human epidermal growth factor receptor 2 (HER2), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR).

Non-receptor tyrosine kinase inhibitors include BCR-ABL tyrosine-kinase inhibitors, mesenchymal-epithelial transition growth factor (c-MET), Janus kinase (JAK) Inhibitor, and spleen tyrosine kinase (SYK) inhibitors. Based on treatment type, the global tyrosine kinase inhibitors market can be classified into first-line treatment, second-line treatment, and third-line treatment. If first-line treatment does not work because of intolerance to a particular drug or drug resistance, then the second-line treatment is given. If both the initial treatment and subsequent treatment (second-line) fail to work, a third treatment option (third-line treatment) can be offered to patients. Three TKI drugs have been approved as initial therapy (first-line treatment) for chronic phase CML. These drugs are Imatinib mesylate (Gleevec), Nilotinib (Tasigna), and Dasatinib (Sprycel). In case of resistance to second-line treatments, other TKI options (third-line treatment) include drugs such as Bosutinib (Bosulif) and Ponatinib (Iclusig). In terms of end-user, the global tyrosine kinase inhibitors market can be divided into pharmaceutical companies, private & government research institutes, academic institutes, and health care facilities.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40667

The global tyrosine kinase inhibitors market is growing at a rapid pace, with numerous products at various phases of industry lifecycle. Significant investments in research and development is attributed to the growth of tyrosine kinase inhibitors market. Moreover, increase in the incidence of chronic diseases such as cancer has attracted several pharmaceutical companies to invest in tyrosine kinase inhibitors market. Imatinib (protein-tyrosine kinase inhibitor) for CML treatment by Novartis was the first to enter the global tyrosine kinase inhibitors market.

Small molecule-based targeted therapeutics can give tough competition to widely accepted monoclonal antibodies in terms of pharmacological efficacy. However, pricing and commercialization strategies are also expected to play a major role. Risk factors associated with the usage of tyrosine kinase inhibitors and the ability to interact with other drugs are the major factors restraining tyrosine kinase inhibitors market. Patients with a history of peripheral vascular disease and cardiac disease need to be monitored carefully and frequently during TKI treatment. TKIs can have serious interactions with other prescription medications, over-the-counter medications, supplements, and even certain foods.

Request to View ToC of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=40667

The global tyrosine kinase inhibitors market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are expected to account for significant share of the global tyrosine kinase inhibitors market owing to rise in technological advancements in medical research and availability of high-tech health care infrastructure. Additionally, increase in number of clinical trials is projected to fuel the growth of the tyrosine kinase inhibitors market in these two regions.

Presence of leading players in these regions is likely to augment tyrosine kinase inhibitors market in the next few years. Furthermore, rise in incidence of various types of cancers and increase in disposable income of consumers, especially in emerging nations such as China and India are expected to fuel the growth of the tyrosine kinase inhibitors market in Asia Pacific. High awareness about the availability of tyrosine kinase inhibitors and rise in adoption of advanced technologies in cancer treatment are the factors anticipated to propel the tyrosine kinase inhibitors market in Latin America and the Middle East.

Leading players operating in the global kinase inhibitors market are Roche, Novartis, AstraZeneca, Bayer, Pfizer, and GlaxoSmithKline.

View Report -

https://www.transparencymarketresearch.com/tyrosine-kinase-inhibitors-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.